STRO
Closed
Sutro Biopharma
0.68
-0.03 (-4.20%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.7139
Day's Range: 0.6736 - 0.7256
Send
sign up or login to leave a comment!
When Written:
4.325
Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company located in South San Francisco, California. The company was founded in 2003 and focuses on developing novel cancer therapies using its proprietary cell-free protein synthesis platform, XpressCF.
Sutro Biopharma's technology allows for the rapid and efficient production of complex proteins, including antibodies and cytokines, with high purity and specificity. The company's lead product candidate, STRO-001, is a CD74-targeting antibody-drug conjugate being developed for the treatment of multiple myeloma and non-Hodgkin lymphoma.
In addition to STRO-001, Sutro Biopharma has a pipeline of other product candidates in various stages of preclinical and clinical development, including STRO-002, a folate receptor alpha-targeting ADC for ovarian and endometrial cancers, and STRO-004, a DLL4-targeting ADC for solid tumors.
Sutro Biopharma has partnerships and collaborations with several pharmaceutical companies, including Merck, Celgene, and EMD Serono. The company went public in 2018 and is traded on the Nasdaq under the ticker symbol STRO.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sutro Biopharma's technology allows for the rapid and efficient production of complex proteins, including antibodies and cytokines, with high purity and specificity. The company's lead product candidate, STRO-001, is a CD74-targeting antibody-drug conjugate being developed for the treatment of multiple myeloma and non-Hodgkin lymphoma.
In addition to STRO-001, Sutro Biopharma has a pipeline of other product candidates in various stages of preclinical and clinical development, including STRO-002, a folate receptor alpha-targeting ADC for ovarian and endometrial cancers, and STRO-004, a DLL4-targeting ADC for solid tumors.
Sutro Biopharma has partnerships and collaborations with several pharmaceutical companies, including Merck, Celgene, and EMD Serono. The company went public in 2018 and is traded on the Nasdaq under the ticker symbol STRO.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!